Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
New Delhi, Oct 23 (PTI) Drug firm Zydus Cadila on Friday said it has received approval from the US health regulator to market Albuterol tablets, used to treat shortness of breath caused by breathing problems like asthma. The company has received final approval from the US Food and Drug Administration (USFDA) to market its product, which is a generic version of Proventil tablets, Zydus Cadila said in a statement.
Albuterol is a bronchodilator that can help open up the airways in the lungs to make it easier to breathe. The medication is used to treat and to prevent bronchospasm.
The drug firm said the product could be manufactured at the group”s formula manufacturing center at SEZ, Ahmedabad.
Zydus Cadila now has 310 approvals and thus far filed over 390 abbreviated new drug applications (ANDAs) since the initiation of the filing process in 2003-04. PTI MSS BAL BAL
